Pathogenesis of Guillain–Barré syndrome

References

• Guillain G, Barre JA, Strohl A. Sur un syndrome de radioculo-nevrite avec huyperalbuminose du liquide cephalorachidien sans reaction cellulaire: Remarques sur les caracters cliniques et graphiques des reflexes tendineux. Bull. Soc. Med. Hop. Paris 40,1462–1470 (1916).
   Google Scholar
• AsbutyAK, Comblath DR Assessment of current diagnostic criteria for Guillain—Barre syndrome. Ann. Neural 27, S21–524 (1990).
   PubMed Web of Science ®Google Scholar
• Thomas PK The Guillain—Barre Syndrome: no longer a simple concept./ Neural 239,361–362 (1992).
   PubMed Web of Science ®Google Scholar
• Asbury AK. New concepts of Guillain—Barre syndrome./ Child NeuroL15, 183–191 (2000).
   Google Scholar
• •Provides a good summary of the clinical aspects and pathology of GBS subtypes.
   Google Scholar
• Ad Hov Committee WHO-AIREN. Acute onset flaccid paralysis. World Health Organization, Geneva, Switzerland (1993).
   Google Scholar
• Asbury AK, McKhann GM. Changing views of Guillain-Barre syndrome. Ann. Neural 41,287–288 (1997).
   PubMed Web of Science ®Google Scholar
• Van der Meche FG, Van Doom PA, Meulstee J, Jennekens FG, the GBS-consensus group of the Dutch Neuromuscular Research Support Centre. Diagnostic and dassification criteria for the Guillain-Barre Syndrome. Eur. Neural 45,133–139 (2001).
   PubMed Web of Science ®Google Scholar
• Dingle KE, Van Den Braak N, Cones FM, et al . Sequence typing confirms that Campylobacter jejuni strains associated with Guillain-Barre and Miller-Fisher syndromes are of diverse genetic lineage, seortype and flagella type. J. Clin. Microbial 39, 3346–3349 (2001).
   PubMed Web of Science ®Google Scholar
• Yuki N. Infectious origins of and molecular mimicry in, Guillain—Barre and Fisher syndromes. Lancet Infect. Dis. 1, 29–37 (2001).
   Google Scholar
• ••A comprehensive review on current viewsof infections related to GBS with diagratntnatical explanation of the pathogenic mechanisms with emphasis on the Fisher syndrome.
   Google Scholar
• Jacobs BC, Rothbarth PH, Van der Meche FG, et al. The spectrum of antecedent infections in Guillain—Barre syndrome: a case-control study. Neurology 51, 1110–1115 (1998).
   PubMed Web of Science ®Google Scholar
• Hadden RD, Karch H, Hartung HP Preceding infections, immune factors and outcome in Guillain—Barre syndrome. Neurology 56,758-765 (2001).seThis large multicenter study involvingpatients from 11 countries described preceding infections, antibodies togangliosides, adhesion molecules, cytokine receptors and clinical features associated with GBS.
   Google Scholar
• Tsang RSW The relationship of Campylobacterjejuni infection and the development of Guillain—Barre syndrome. Curr. Opin. Infect. Dis. 15, 221–228 (2002).
   PubMed Web of Science ®Google Scholar
• Visser LH, Van der Meche FG, Meulstee J, et al . Cytomegalovirus infection and Guillain—Barre syndrome: the clinical, electrophysiological and prognostic features, Dutch Guillain—Barre Study Group. Neural. 47,668–673 (1996).
   Google Scholar
• Griffin JW, Li CY, Ho TW, et al Guillain—Barre syndrome in northern China, the spectrum of neuropathologic changes in clinically defined cases. Brain 118, 577–595 (1995).
   PubMed Web of Science ®Google Scholar
• Lu JL, Sheikh KA, Wu HS, et al Physiologic—pathologic correlation in Guillain—Barre syndrome. Neurology 54, 33–39 (2000).
   PubMed Web of Science ®Google Scholar
• Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine 48, 173–215 (1969).
   PubMed Web of Science ®Google Scholar
• Hafer-Macko C, Hsieh ST, Li CY, et al Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann. Neural 40,635–644 (1996).
   PubMed Web of Science ®Google Scholar
• Ho TW, Willison HJ, Nachamkin I, et al AntiGDla antibody is associated with axonal but not demyelinating forms of Guillain—Barre syndrome. Ann. Neural 45, 168–173 (1999).
   PubMed Web of Science ®Google Scholar
• Gold R, Hartung HP Toyka KV Animalmodels for autoimmune demyelinating disorders of the nervous system. Mal Med Today 6, 88–91 (2000).
   PubMedGoogle Scholar
• Brostoff SW, Levit S, Powers JM. Induction of experimental allergic neuritis with a peptide from myeline P2 basic protein. Nature 268, 752–753 (1977).
   PubMed Web of Science ®Google Scholar
• Linington C, Lassmann H, Ozawa K, Kosin S, Mongan L Cell adhesion molecules of the immunoglobulin supergene family as tissue-specific autoantigens: induction of experimental allergic neuritis (EAN) by PO protein-specific T-cell lines. Eur. j Immunot 22, 1813–1817 (1992).
   PubMed Web of Science ®Google Scholar
• Abromson-Leeman S, Bronson R, Dorf ME. Experimental autoimmune peripheral neuritis induced in Balb/c mice by myelin basic protein-specific T-cell clones. J. Bcp. Med 182, 587–592 (1995).
   Google Scholar
• Gabriel CM, Hughes RA, Moore SE, Smith KJ, Walsh FS. Induction of experimental autoimmune neuritis with peripheral myelin protein-22. Brain 121, 1895–1902 (1998).
   PubMed Web of Science ®Google Scholar
• Weerth S, Berger T, Lassmann H, Linington C. Encephalitogenic and neuritogenic T-cell responses to the myelinassociated glycoprotein (MAG) in the Lewis rat./ Neuroimmund 95, 157–164(1999).
   PubMed Web of Science ®Google Scholar
• Heininger K, Stoll G, Linington C, Toyka KV, Wekerle H. Conduction failure and nerve conduction slowing in experimental allergic neuritis induced by P2-specific T-cell lines. Ann. Neural 19, 44 49 (1986).
   Web of Science ®Google Scholar
• Previtali SC, Feltri ML, Archelos JJ, Quattrini A, Wrabetz L, Hartung HP Role of integrins in the peripheral nervous system. Prog. Neurbial 64, 35–49 (2001).
   PubMed Web of Science ®Google Scholar
• Ho TW, McKbann GM, Griffin JW Human antoimmune neuropathies. Ann. Rev. Neurosci. 21, 187–226 (1998).
   PubMedGoogle Scholar
• Press R, Mata S, Lolli F, Zhu J, Andersson T, Link H. Temporal profile of antiganglioside antibodies and their relation to clinical parameters and treatment in GBS. j Neural. Sci. 190, 41–47 (2001).
   PubMed Web of Science ®Google Scholar
• Van Koningsveld R, Schmitz PI, Mg CW, et al Infections and course of disease in mild forms of Guillain—Barre syndrome. Neurology 58, 610–614 (2002).
   PubMed Web of Science ®Google Scholar
• Gilbert M, Brisson JR, Karwaski MF, et al. Biosynthesis of ganglioside mimics in Campylobacterjtjuni. J. Biol. Chem. 275, 3896–3906 (2000).
   PubMed Web of Science ®Google Scholar
• Moran AP Prendergast MM. Molecular mimicry in Campylobacterjejuni and Helicobacter pylori lipopolysaccharides: contribution of gastrointestinal infections to autoimmunity. j Autoimmun. 16, 241–256 (2001).
   Web of Science ®Google Scholar
• Kusunoki S, Shiina M, Kanazawa I. AntiGal-C antibodies in GBS subsequent to mycoplasma infection: evidence of molecular mimicry. Neurology 57, 736–738 (2001).
   PubMed Web of Science ®Google Scholar
• Yuki N, Yamada M, Koga M, et al Animal model of axonal Goillain—Barre syndrome induced by sensiti72rion with GM1 ganglloside. An, Neural 49,712–720 (2001).
   PubMed Web of Science ®Google Scholar
• Plomp JJ, Molenaar PC, O'Hanlon GM, et al Miller Fisher antiGQ1b antibodies: a-latrotoxin-like effects on motor-end plates. Ann. Neural 45, 189–199 (1999).
   PubMed Web of Science ®Google Scholar
• Yan WX, Taylor J, Andrias-Kauba S, Pollard JD. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann. Neural 47, 765–775 (2000).
   PubMed Web of Science ®Google Scholar
• The Guillain—Barre Study Group. Plasmapheresis and acute Guillain—Barre syndrome. Neurology 35, 1096–1104 (1985).
   PubMed Web of Science ®Google Scholar
• Van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain—Barre syndrome. Dutch Guillain—Barre Study Group. N Engl. J. Med. 328, 1123–1129 (1992).
   Google Scholar
• Sheikh KA, Griffin JW Variants of the Guillain—Barre syndrome: progress toward fulfilling Koch's postulates. An, Neural. 49, 694–696 (2001).
   PubMed Web of Science ®Google Scholar
• ••Summarizes recent findings on GBS andAMAN that fulfil requirements to satisfy Koch's postulates for the pathogenesis of GBS.
   Google Scholar
• Kusunoki S. Antiglycolipid antibodies in Guillain—Barre syndrome and autoimmune neuropathies. Am. J. Med. Sci. 319, 234–239 (2000).
   PubMed Web of Science ®Google Scholar
• Chiba A, Kusunoki S, Shimizu S,Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann. Neural 31, 677–679 (1992).
   PubMed Web of Science ®Google Scholar
• Willison HJ, Veitch J, Patterson G, Kennedy PG. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside.j Neural Neurosurg. Psychiatry 56, 204–206 (1993).
   PubMed Web of Science ®Google Scholar
• Jacobs BC, Bullens RW, O= Hanlon GM, Mg CW, Willison HJ, Plompfl. Detection and prevalence of a-latrotoxin-like effects of serum from patients with Guillain—Barre syndrome. Muscle Nerve 25, 549–558 (2002).
   PubMed Web of Science ®Google Scholar
• Yuki N, Ang CW, Koga M, et al Clinical features and response to treatment in Guillain Barre syndrome associated with antibodies to GMlb ganglioside. Ann. Neural 47, 314–321(2000).
   PubMed Web of Science ®Google Scholar
• Koga M, Yoshino H, Morimatsu M, Yuki N. AntiGTla IgG in Guillain—Barre syndrome./ Neural Neurosurg. Psychiatry 72, 767–771 (2002).
   PubMed Web of Science ®Google Scholar
• Yuki N, Yoshino H, Sato S, Shinozawa K, Miyatake T Severe acute axonal form of Guillain-Barre syndrome associated with IgG antiGDla antibody. Muscle Nerve 15, 899–903 (1992).
   PubMed Web of Science ®Google Scholar
• Hao Q, Saida T, Yoshino H, Kuroki S, Nukina M, Saida K AntiGalNAc-GDla antibody-associated Guillain—Barre syndrome with a predominantly distal weakness without cranial nerve impairment and sensory disturbance. Ann. Neural 45, 758–768 (1999).
   PubMed Web of Science ®Google Scholar
• Kwa MS, van Schaik IN, De Jonge RR, et al Autoimmunoreactivity in Schwann cells in patients wth inflammatory neropathies. Brain 126,361–375 (2002).
   Web of Science ®Google Scholar
• Ang CW, Laman JD, Willison HJ, et al Structure of Campylobacterjtjuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain—Barre and Miller Fisher patients. Infect. Immun. 70,1202–1208 (2002).
   PubMed Web of Science ®Google Scholar
• Chiba A, Kusunoki S, Obata H,Machinami R, Kanazawa I. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res. 745, 32–36 (1997).
   PubMed Web of Science ®Google Scholar
• Hanlon GM, Plomp JJ, Chakfrabarti M, et al AntiGQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain 124,893–906 (2001).
   PubMed Web of Science ®Google Scholar
• Mod M, Kuwabara S, Miyake M, et al Haemophilus influenzae has a GM1 ganglioside-like structure and elicits Guillain—Barre syndrome. Neurology 52, 1282–1284 (1999).
   PubMed Web of Science ®Google Scholar
• Schmidt B, Toyka KV, Kiefer R, Ful1J,Hartung HP Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain—Barre syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 19,474 487 (1996).
   Web of Science ®Google Scholar
• Khalili Shirazi A. Hughes RA, Brostoff SW,Linington C, Gregson N. T-cell responses to myelin proteins in Guillain-Barre syndrome. J. Neural Sci. 111,200–203(1992).
   PubMed Web of Science ®Google Scholar
• Van Rhijn I, Bleumink-Pluym NM, VanPutten JP Van den Berg LH. Campylobacter DNA is present in circulating myelomonocytic cells of healthy persons and in persons with Guillain—Barre syndrome."Dis. 185,262–265 (2002).
   Google Scholar
• Cooper JC, Ben-Smith A, Savage CO,Winer JB. Unusual T-cell receptor phenotype V gene usage of y8 T-cells in a line derived from the peripheral nerve of a patient with Guillain—Barre syndrome." Neural Neurosurg. Psychiatry 69,522–524 (2001).
   Web of Science ®Google Scholar
• •Demonstrates a possible link exists between gastroenteric infections and development of neurological disease by demonstrating the presence of y8 T-cells which are normally found in theintestines, are also found in a sural nerve biopsy taken from a GBS patient.
   Google Scholar
• Ilyas AA, Chen ZW, Cook SD, Mithen FA, Singhal BS. Immunoglobulin G subclass distribution and autoantibodies to gangliosides in patients with Guillain—Barre syndrome. Res. Commun. Mot Pathol Pharmacol 109,115–123 (2001).
   PubMedGoogle Scholar
• Sieling PA, Chatterjee D, Porcelli SA, et al. CD1-restricted T-cell recognition of microbial lipoglycan antigens. Science 269, 227–230 (1995).
   PubMed Web of Science ®Google Scholar
• Khalili-Shirazi ANA, Londel M, Summers L, Hughes RA. Gregson. The distribution of CD1 molecules in inflammatory neuropathy. j Neural Sci. 158,154–163 (1998).
   PubMed Web of Science ®Google Scholar
• Linington C, Izumo S, Suzuki M, UyemuraK Meyermann R Wekerle H. A permanent rat T-cell line that mediates experimental allergic neuritis in the Lewis rat in vivo. j Immund 133,1946–1950 (1984).
   PubMed Web of Science ®Google Scholar
• Brosnan JV, Craggs RI, King RH, ThomasPK Reduced susceptibility of T-cell deficient rats to induction of experimental allergic neuritis." Neuroimmunol. 14, 267–282 (1987).
   PubMedGoogle Scholar
• Jung S, Kramer S, Schluesener HJ, Hunig T,Toyka K, Hartung HP Prevention and therapy of experimental autoimmune neuritis by an antibody against T-cell receptor-a/I3 Immund 148,3768–3775 (1992).
   PubMed Web of Science ®Google Scholar
• Hartung HP, Schafer B, Diamantstein T, FierzW, Heininger K, Toyka KV Suppression of P2-T-cell line-mediated experimental autoimmune neuritis by intelleukin-2 receptor targeted monoclonal antibody ART Brain Res. 489,120–128 (1989).
   PubMed Web of Science ®Google Scholar
• Zhu Y, Ljunggren H-G, Mix E, et al CD28-B7 costimulation: a critical role for initation and development of experimental autoimmune neuritis in C57BL/6 mice. J. Neuroimmunol. 114,114–121 (2001).
   PubMed Web of Science ®Google Scholar
• Zhu Y, Bao L, Zhu S, et al CD4 and CD8 T-cells but not B-cells, are critical to the control of murine experimental autoimmune neuritis. Exp. Neural. 177, 314–320 (2002).
   PubMed Web of Science ®Google Scholar
• Hartung HP Willson, HJ, Keiseier BC. Acute immunoinflammatory neuropathy: update on Guillain—Barre syndrome. Curr. Opin. Neural. 15,571–577 (2002).
   PubMed Web of Science ®Google Scholar
• ••The immunopathogenic mechanisms indemylinating neuropathy is succinctly presented.
   Google Scholar
• Orlikowski D, Chamud B, Plonquet A, et al. Monocyte chemoattractant protein 1 and chemokine receptor CCR2 productions in Guillain—Barre syndrome and experimental autoimmune neuritis. J. Neuroimmunol. 134,118–127 (2003).
   PubMed Web of Science ®Google Scholar
• •A well-designed investigation that tracked down the levels of monocytic chemoattractant protein 1 and its receptor during the clinical progress of GBS.
   Google Scholar
• Kieseier BC, Tani M, Mahad D, et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain 125, 823–834 (2002).
   PubMed Web of Science ®Google Scholar
• •In this investigation, the expression patterns of specific chemokine and chemokine receptors in sural nerve biopsies from GBS patients were described, induding the pathogenic role of specific chemokine receptor and cytokine.
   Google Scholar
• Zou LP, Pelidou SH, Abbas N, et al. Dynamics of production of MIP-1 MCP-1 and MIP-2 and potential role of neutralization of these chemokines in the regulation of immune responses during experimental autoimmune neuritis in Lewis rats/ Neuroimmunol. 98,168–175 (1999).
   PubMed Web of Science ®Google Scholar
• Stoll G. Inflammatory cytokines in the nervous system: multifunctional mediators in autoimmunity and cerebral ischaemia. Rev. Neural 158,887–891 (2002).
   PubMedGoogle Scholar
• ••An Excellent review on the effects ofcytokines in immune-mediated demyelination.
   Google Scholar
• Mossman TR, Fowell DJ. The Th1/Th2paradigm in infections. In: Immunology and Infectious Disease. Kaufmann SHE, Sher A, Ahmed R (Eds). ASM Press, London, UK 163–174 (2002).
   Google Scholar
• Jander S, Stoll G. Interleukin-18 is induced in acute inflammatory demyelinating polyneuropathy. j Neuroimmunol. 114, 253–258 (2001).
   Google Scholar
• Kapoor R, Davies M, Blaker PA, Hall SM, Smith KJ. Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann. Neural 53, 174–180 (2003).
   PubMed Web of Science ®Google Scholar
• Yu S, Chen Z, Mix E, et al Neutralizing antibodies to IL-18 ameliorate experimental autoimmune neuritis by counter-regulation of autoreactive Thl responses to peripheral myelin antigen./ Neuropathol Exp. Neural 61,614–622(2002).
   PubMed Web of Science ®Google Scholar
• Zhu J, Bai XF, Mix E, Link H. Cytokine dichotomy in the peripheral nervous system influences the outcome of experimental allergic neuritis: dynamics of mRNA expression for IL-113, IL-6, IL-10, IL-12, TNF-a and TNF-I3 and cytolysin. Clin. Immunol. Immunopathol. 84,85–94 (1997).
   PubMedGoogle Scholar
• Pelidou SH, Zou LP Deretzi G, et al . Intranasal administration of recombinant IL-12 increases inflamation and demyelination in chronic experimental autoimmune neuritis in Lewis rats. Scand. j Immunot 51,29–35 (2000).
   PubMed Web of Science ®Google Scholar
• Bao L, Lindgren JU, van der Meide P ZhuS, Ljunggren HG, Zhu J. The critical role of IL-12p40 in initiating, enhancing and perpetuating pathogenic events in murine experimental autoimmune neuritis. Brain Pathol 12,420–429 (2002).
   PubMed Web of Science ®Google Scholar
• Press R, Deretzi G, Thu LP, et al IL-10 and IFN-y in Guillain—Barre syndrome. Network Members of the Swedish Epidemiological Study Group. J. Neuroimmunol. 112, (129–138 (2001).
   PubMed Web of Science ®Google Scholar
• •This study did not find elevated levels of IFN-y in GBS patients which is in contrast with EAN where activity of IFN-y has been dearly demonstrated.
   Google Scholar
• Laura M, Gregson NA, Curmi Y, Hughes RA. Efficacy of leukemia inhibitory factor in experimental autoimmune neuritis. J. Neuroimmunol. 133,56–59 (2002).
   PubMed Web of Science ®Google Scholar
• Kurek JB, Radford AJ, Crump DE, et al LIF (AI\4424), a promising growth factor for the treatment of ALS. J. Neural Sci. 160\(Suppl. 1), S106—S113 (1998).
   PubMedGoogle Scholar
• Sharief MK, Mclean B, Thompson EJ. Circulating tumor necrosis factor-a correlates with electrodiagnostic abnormalities in Guillain—Barre syndrome. Ann. Neural 42,68–73 (1997).
   PubMed Web of Science ®Google Scholar
• Bao L, Lindgren JU, Zhu Y, Ljunggren HG, Zhu J. Exogenous soluble tumor necrosis factor receptor Type 1 ameliorates murine experimental autoimmune neuritis. Neurobial Dis. 12,73–81 (2003).
   PubMed Web of Science ®Google Scholar
• Beg AA, Finco TS, Nantermet PV, Baldwin AS Jr. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of 1 icBcc: a mechanism for NF-ic B activation. Mot Cell. Bial 13, 3301–3310 (1993).
   Web of Science ®Google Scholar
• Kohno K, Kataoka J, Ohtsuki T, et al. IFN-a-inducing factor (IGIF) is a costimulatory factor on the activation of Thl but not Th2 cells and exerts its effect independently of IL-12.j Immunot 158, 1541–1550 (1997).
   Google Scholar
• Olee T, Hashimoto S, Quach J, Lotz M. IL-18 is produced by articular chondrocytes and induces pro-inflammatory and catabolic responses. J. Immunot 162, 1096–1100 (1999).
   Google Scholar
• Yu S, Chen Z, Mix E, et al Neutralizing antibodies to IL-18 ameliorates experimental autoimmune neuritis by counter-regulation of autoreactive Thl responses to peripheral myelin antigen./ Neuropathol Exp. Neural 61,614–623(2002).
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immurzol 70,83–243 (1998).
   PubMed Web of Science ®Google Scholar
• Deretzi G, Zou LP, Pelidou SH, et al Nasal administration of recombinant IL-4 ameliorates ongoing experimental autoimmune neuritis and inhibits demyelination.j Autoimmurz. 12,81–89 (1999).
   PubMed Web of Science ®Google Scholar
• Bai XF, Zhu J, Zhang GX, et al IL-10 suppresses experimental autoimmune neuritis and downregulates Th-1 type immune responses. Clirz. Immurzol Immunopathol 83,117–126 (1997).
   PubMedGoogle Scholar
• all j, Mix E, Link H. Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain—Barre syndrome. J. Neuroimmunol. 84,40–52 (1998).
   PubMed Web of Science ®Google Scholar
• ••Summarizes the complexity of thecytokine network that is important in both GBS and EAN.
   Google Scholar
• Cunningham MW Cardiac myosin and the Thl/Th2 paradigm in autoimmune myocarditis. Am. J. Pathol 159,5–12 (2001).
   PubMed Web of Science ®Google Scholar
• Govoni V, Granieri E. Epidemiology of the Guillain-Barre syndrome. Curr. Opin. Neural 14,605–613 (2001).
   PubMed Web of Science ®Google Scholar
• •Various aspects of GBS epidemiology was described, including effect of sex, age and preceding events.
   Google Scholar
• Ang CW, van Doom PA, Endtz HP, et al A case of Guillain—Barre syndrome following a family outbreak of Campylobacterjtjuni enteritis. J. Neuroimmunol. 111,229–233 (2000).
   PubMed Web of Science ®Google Scholar
• •An interesting paper that showed striking differences in the immune responses of different family members towards a family outbreak of Campylobacter jejuni enteritis.
   Google Scholar
• Hughes RA, Rees JH. Clinical and epidemiological features of Guillain—Barre syndrome. J. Infect. Dis. 176\(Suppl. 2), S92—S98 (1997).
   PubMedGoogle Scholar
• Dahlman I, Wallstrom E, Jiao H, Luthman H, Olsson T, Weissert R Phylogenic control of autoimmune peripheral nerve inflammation in rat./ Neuroimmunol. 119, 166–174 (2001).
   Google Scholar
• Koga M, Yuki N, Kashiwase K, Tadokoro K, Juji T, Hirata K. Guillain—Barre and Fisher's syndromes subsequent to Campylobacterjejuni enteritis are associated with HLA-B54 and Cwl independent of antiganglioside antibodies. J. Neuroimmunol. 88,62–66 (1998).
   PubMed Web of Science ®Google Scholar
• Rees JH, Vaughan RW, Kondeatis E, Hughes RA. HLA-class II alleles in Guillain—Barre syndrome and Miller Fisher syndrome and their association with preceding Campylobacterjtjuni infection./ Neuroimmunol. 62,53–57 (1995).
   Google Scholar
• Magira EE, Papaiakim M, Nachamkin I, et al. Differential distribution of HLA-DQ I3/DR beta epitopes in the two forms of Guillain—Barre syndrome, acute motor axonal neuropathy and acute inflammatory demyelinatingpolyneuropathy (AIDP): identification of DQ 13 epitopes associated with susceptibility to and protection from AIDPJ Immunot 170,3074–3080 (2003).
   Google Scholar
• Van der Pol WL, Van den Berg LH, Scheepers RH, et al IgG receptor Ha alleles determine susceptibility and severity of Guillain—Barre Syndrome. Neurology 54, 1661–1665 (2000).
   PubMed Web of Science ®Google Scholar
• Plasma F, xchange/Sandoglobulin Guillain—Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin and combined treatments in Guillain—Barre syndrome. Lancet 349,225–230 (1997).
   PubMed Web of Science ®Google Scholar
• Guillain—Barre Syndrome Steroid Therapy Group. Double-blind trail of intravenous methylprednisolone in Guillain—Barre syndrome. Lancet 341,586–590 (1993).
   PubMed Web of Science ®Google Scholar
• van Koningsveld RM, Schmitz PI, van Doom PA. Combined therapy of intravenous immune globulin and methylprednisolone in patients with Guillain—Barre Syndrome. The results of a multicentre double-blind controlled clinical trial. J. Peripher. Nerv. Syst. 41, 586–590 (2001) (Abstract).
   Google Scholar
• King RHM, Craggs RI, Gross MLP, Thomas PK Effects of glucocorticoids on experimental allergic neuritis. Exp. Neural 87,9–19 (1985).
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 59, S13—S21 (2002).
   Web of Science ®Google Scholar
• ••A comprehensive review on the potentialmechanisms of intravenous immunoglobulin therapy for the treatment of neuropathies.
   Google Scholar
• Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain—Barre syndrome. Ann. Neural 51, 673–680 (2002).
   PubMed Web of Science ®Google Scholar
• Kambara C, Matsuo, H, Fukudome T, Goto H, Shibuya N. Miller Fisher syndrome and plasmapheresis, Ther. Apher. 6,450–453 (2002).
   PubMedGoogle Scholar
• Diener HC, Haupt WF, Coss TM, et al A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange and immune adsorption in Guillain—Barre syndrome. Eur. Neural 46,107–108 (2001).
   PubMed Web of Science ®Google Scholar
• Sdchaller B, Radziwill AJ, Stock AJ. Successful treatment of Guillain—Barre syndrome with combined administration of interferon-13-1a and intravenous immunoglobulin. Eur Neural 46,167–168 (2001).
   PubMed Web of Science ®Google Scholar
• Wollinsky ICH, Husler PJ, Brinkmeier H, et al CSF filtration is an effective treatment of Guillain—Barre syndrome. Neurology 57, 774–780 (2001).
   PubMed Web of Science ®Google Scholar
• Zou LP, Abbas N, Volkmann I, et al Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells in the peripheral nerve tissue. Neuropharmacology 42,731-739 (2002).Ho Li CY, Xue P, Tian WQ, Liu RC, Yang C. Experimental Campylobacter jtjuni infection in the chicken: an animal model of axonal Guillain—Barre syndrome. J. Neural Neurosurg. Psychiatry 61,279–284 (1996).
   PubMedGoogle Scholar
• •The chicken model described in this report may be the only animal model of GBS induced by Campylobacter jduni, however there has not been other reports that confirmed this finding.
   Google Scholar